Clin2
NCT03579875Possibly a fitRecruiting

Testing an inherited bone marrow transplant approach for rare blood disorders

Fanconi AnemiaSevere Aplastic AnemiaMyelodysplastic SyndromesT Cell Receptor Alpha/Beta DepletionTelomere Biology DisorderBone Marrow FailureDyskeratosis CongenitaTelomere Biology Disorders

Treatments studied

Part of Blood & lymphatic, Genetic & congenital, Hormones & metabolism, Skin clinical trials.

This Phase 2 study tests a special “T-cell depleted” transplant plan for people with inherited bone marrow failure disorders (Fanconi anemia or T-Beta-thalassemia—or “TBD”). It may help restore healthy blood production while lowering the chance of certain transplant complications.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
48 people
Ages
Up to 65 years
Study type
Interventional

Who can take part

  • You have Fanconi anemia or TBD (an inherited bone marrow failure condition)
  • Your age is under 65 for Fanconi anemia, or under 70 for TBD
  • You have a serious risk situation like severe aplastic anemia, myelodysplasia, a high-risk genetics pattern, or immune problems with frequent infections
  • Your heart/lung/liver function is good enough for transplant (the team will check labs and tests)
  • You (or your parent/guardian) can sign consent to take part in study procedures
  • You are not currently pregnant or breastfeeding (and need a recent negative pregnancy test if you can become pregnant)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07493538Recruiting· Phase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers

This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.

Minneapolis, Minnesota
NCT05805605Recruiting· Phase 2
Low-intensity stem cell transplant with donor cells and blood-protection

This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.

Minneapolis, Minnesota
NCT04232085Recruiting· Phase 2
Stem cell transplant to rebuild immunity in genetic immune disorders

This Phase 2 trial tests a stem cell (bone marrow) transplant approach to restore bone marrow function and immune function in people with certain inherited immune problems. If you have one of these conditions and a suitable donor, the study may offer a path to rebuild blood and immune systems.

Baltimore, Maryland
NCT02143830Recruiting· Phase 2
Stem cell transplant chemotherapy for Fanconi anemia

This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.

New York, New York
NCT01174108Recruiting· Phase 2
Stem cell transplant with donor T-cells for severe bone marrow failure

This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.

Baltimore, Maryland
NCT04099966Recruiting· Phase 2
Stem cell transplant to treat high-risk blood cancers

This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.

Valhalla, New York

Hear when a new Fanconi Anemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.